DE69731763D1 - Pharmazeutische zusammenstellung die eine verbindung mit anti-xa eigenschaften und eine verbindung die ein plakettenagregations antagonist is enthalten - Google Patents

Pharmazeutische zusammenstellung die eine verbindung mit anti-xa eigenschaften und eine verbindung die ein plakettenagregations antagonist is enthalten

Info

Publication number
DE69731763D1
DE69731763D1 DE69731763T DE69731763T DE69731763D1 DE 69731763 D1 DE69731763 D1 DE 69731763D1 DE 69731763 T DE69731763 T DE 69731763T DE 69731763 T DE69731763 T DE 69731763T DE 69731763 D1 DE69731763 D1 DE 69731763D1
Authority
DE
Germany
Prior art keywords
agregation
compilation
plaque
antagonist
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69731763T
Other languages
English (en)
Other versions
DE69731763T2 (de
DE69731763T3 (de
Inventor
Andre Uzan
H Curaudeau
J Leadley
T Dunwiddie
H Perrone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Rhone Poulenc Rorer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21861879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69731763(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Pharmaceuticals Inc filed Critical Rhone Poulenc Rorer Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69731763D1 publication Critical patent/DE69731763D1/de
Publication of DE69731763T2 publication Critical patent/DE69731763T2/de
Publication of DE69731763T3 publication Critical patent/DE69731763T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69731763T 1996-11-27 1997-11-24 Pharmazeutische Zusammenstellung, die eine Verbindung mit Anti-Xa-Eigenschaften und eine Verbindung, die ein Plakettenaggregationsantagonist ist, enthalten Expired - Lifetime DE69731763T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3187896P 1996-11-27 1996-11-27
US31878P 1996-11-27
PCT/US1997/021440 WO1998023279A1 (en) 1996-11-27 1997-11-24 PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND

Publications (3)

Publication Number Publication Date
DE69731763D1 true DE69731763D1 (de) 2004-12-30
DE69731763T2 DE69731763T2 (de) 2005-06-30
DE69731763T3 DE69731763T3 (de) 2010-12-30

Family

ID=21861879

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731763T Expired - Lifetime DE69731763T3 (de) 1996-11-27 1997-11-24 Pharmazeutische Zusammenstellung, die eine Verbindung mit Anti-Xa-Eigenschaften und eine Verbindung, die ein Plakettenaggregationsantagonist ist, enthalten

Country Status (28)

Country Link
US (2) US6103705A (de)
EP (1) EP0946185B2 (de)
JP (1) JP4498471B2 (de)
KR (1) KR100512671B1 (de)
CN (1) CN1121224C (de)
AP (1) AP1390A (de)
AT (1) ATE283062T1 (de)
AU (1) AU754936B2 (de)
BG (1) BG64542B1 (de)
BR (1) BR9713141A (de)
CA (1) CA2272317C (de)
CZ (1) CZ298552B6 (de)
DE (1) DE69731763T3 (de)
DK (1) DK0946185T4 (de)
EA (1) EA002475B1 (de)
ES (1) ES2230624T5 (de)
HK (1) HK1023504A1 (de)
HU (1) HUP9903496A3 (de)
IL (1) IL129877A (de)
NO (1) NO327740B1 (de)
OA (1) OA11049A (de)
PL (1) PL189116B1 (de)
PT (1) PT946185E (de)
SI (1) SI0946185T2 (de)
SK (1) SK286024B6 (de)
UA (1) UA63929C2 (de)
WO (1) WO1998023279A1 (de)
ZA (1) ZA9710691B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4498471B2 (ja) * 1996-11-27 2010-07-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 抗―Ｘａ活性を有する化合物及び血小板凝集拮抗剤化合物を含有する製薬組成物
FR2764511B1 (fr) 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
WO2000029019A1 (en) * 1998-11-18 2000-05-25 G.D. Searle & Co. Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
KR20020032444A (ko) * 1999-06-30 2002-05-03 잭 허쉬 응괴 연관된 응고 인자를 억제하는 헤파린 조성물
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
CA2420890A1 (en) * 2000-09-08 2002-03-14 Hamilton Civic Hospitals Research Development, Inc. Antithrombotic compositions
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
US20040171819A1 (en) * 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
EP1601669B1 (de) 2003-03-07 2008-12-24 Schering Corporation Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN100439361C (zh) * 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
EP1537871A1 (de) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin in der Tumorenbehandlung
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
KR100601429B1 (ko) * 2004-07-09 2006-07-14 주식회사 대우일렉트로닉스 기계식 전자렌지의 댐퍼 구동회로
EP2014296A1 (de) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Neuartige Strategien zur Erhöhung der Reperfusion in einem verstopften Blutgefäß
AR067345A1 (es) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
CN101783857B (zh) * 2009-05-12 2011-11-30 上海海事大学 一种基于fpga在高分辨率成像系统中的图像矩阵化预处理方法
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
EP2508892A1 (de) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Kontrollen und Kit für Thrombozytenaktivitätsteste
RU2554803C1 (ru) * 2014-06-26 2015-06-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики развития послеоперационных венозных тромбоэмболических осложнений у пациентов с колоректальным раком

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766167A (en) * 1971-03-26 1973-10-16 Research Corp Orally active anticoagulant
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
FR2478646A2 (fr) * 1980-03-20 1981-09-25 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
FR2440376A1 (fr) * 1978-11-06 1980-05-30 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
SE449753B (sv) * 1978-11-06 1987-05-18 Choay Sa Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
US4826827A (en) * 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
EP0066908B1 (de) * 1981-05-21 1985-08-28 Akzo N.V. Antithrombotikum auf Basis von Polysacchariden, Verfahren zur dessen Herstellung und medizinale Zusammensetzungen
US4533549A (en) * 1983-01-04 1985-08-06 Lasker Sigmund E Antithrombotic agent
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
DK196986D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
DK196886D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
US4833155A (en) * 1986-11-25 1989-05-23 Syntex (U.S.A.) Inc. 3-(ω-(3,5,-di-t-butyl-4-hydroxyphenyl)-alkanoyl)pyrroles, and anti-inflammatory uses thereof
DE3781263T2 (de) * 1986-12-15 1993-04-08 Inst Nat Sante Rech Med Peptid-derivate und deren verwendung in der therapie.
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
IT1234508B (it) * 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2066047A1 (en) * 1989-09-29 1991-03-30 Scott I. Klein Anti-thrombotic peptides and pseudopeptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5086069A (en) * 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
IL99539A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
DE4290097T1 (de) * 1991-01-24 1993-01-28 Aerojet-General Corp., Rancho Cordova, Calif., Us
WO1992019249A1 (en) * 1991-05-02 1992-11-12 Yeda Research And Development Co. Ltd. Compositions for the prevention and/or treatment of pathological processes
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
PL310896A1 (en) * 1993-03-29 1996-01-08 Du Pont Merck Pharma Cyclic compounds useful as platelet iib/iiia glycoprotein inhibitors
PL181749B1 (pl) * 1993-10-15 2001-09-28 Aventis Pharm Prod Inc Zwiazek do zapobiegania i leczenia zakrzepicy u ssaków oraz oraz kompozycja farmaceutyczna do zapobiegania i leczenia zakrzepicy u ssaków PL PL PL PL PL PL PL PL
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
WO1997035592A1 (en) * 1996-03-28 1997-10-02 G.D. Searle & Co. Iib/iiia antagonists co-administered with aspirin and/or heparin
JP4498471B2 (ja) * 1996-11-27 2010-07-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 抗―Ｘａ活性を有する化合物及び血小板凝集拮抗剤化合物を含有する製薬組成物

Also Published As

Publication number Publication date
DE69731763T2 (de) 2005-06-30
EP0946185B2 (de) 2010-05-05
EA199900499A1 (ru) 2000-04-24
DE69731763T3 (de) 2010-12-30
AP1390A (en) 2005-04-15
DK0946185T4 (da) 2010-08-30
OA11049A (en) 2002-02-18
JP4498471B2 (ja) 2010-07-07
BR9713141A (pt) 2000-02-08
UA63929C2 (uk) 2004-02-16
CN1121224C (zh) 2003-09-17
ES2230624T3 (es) 2005-05-01
KR100512671B1 (ko) 2005-09-07
AP9901517A0 (en) 1999-06-30
EA002475B1 (ru) 2002-06-27
NO327740B1 (no) 2009-09-14
BG103372A (en) 2000-01-31
PT946185E (pt) 2005-02-28
HK1023504A1 (en) 2000-09-15
NO992555L (no) 1999-05-27
HUP9903496A3 (en) 2001-03-28
AU754936B2 (en) 2002-11-28
KR20000057265A (ko) 2000-09-15
EP0946185A1 (de) 1999-10-06
SK286024B6 (sk) 2008-01-07
BG64542B1 (bg) 2005-07-29
SI0946185T2 (sl) 2010-08-31
EP0946185A4 (de) 2001-06-27
SI0946185T1 (en) 2005-06-30
AU5454698A (en) 1998-06-22
PL189116B1 (pl) 2005-06-30
ATE283062T1 (de) 2004-12-15
CA2272317C (en) 2001-01-30
US20020032214A1 (en) 2002-03-14
CN1238693A (zh) 1999-12-15
NO992555D0 (no) 1999-05-27
CZ174299A3 (cs) 1999-09-15
HUP9903496A2 (hu) 2000-10-28
WO1998023279A1 (en) 1998-06-04
EP0946185B1 (de) 2004-11-24
ES2230624T5 (es) 2010-10-25
US6103705A (en) 2000-08-15
CZ298552B6 (cs) 2007-10-31
IL129877A (en) 2004-08-31
ZA9710691B (en) 1998-06-12
IL129877A0 (en) 2000-02-29
JP2001506603A (ja) 2001-05-22
DK0946185T3 (da) 2005-03-21
SK67399A3 (en) 2000-07-11

Similar Documents

Publication Publication Date Title
DE69731763D1 (de) Pharmazeutische zusammenstellung die eine verbindung mit anti-xa eigenschaften und eine verbindung die ein plakettenagregations antagonist is enthalten
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
DE69618587T2 (de) Chinazoline und pharmazeutische zusammensetzungen
DE69525148T2 (de) Pharmazeutische formulierung
DE69600065D1 (de) Dermatologische und/oder pharmazeutische Zubereitung, ihre Herstellung und Anwendung
HUP9901092A3 (en) Benzimidazole compounds and their pharmaceutical use
ATE503478T1 (de) Arzneizubereitung enthaltend irbesartan und ein diuretikum
HU9602104D0 (en) Novel medicines and their use
DE69524402T2 (de) Arzneiabgabevorrichtung und deren konstruktionsmethode
FI932655A (fi) Imidatderivat av farmaceutiskt anvaendbara antikonvulsiva sulfamat
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
DE69626397D1 (de) Darifenacin enthaltende pharmazeutische zubereitungen
ZA963413B (en) Use of retinoids in a cosmetic composition or for the manufacture of a pharmaceutical composition
DE59704397D1 (de) Kosmetische und/oder pharmazeutische zubereitungen
EP0498268A3 (en) 5-oxo-l-proline derivatives and pharmaceutical use thereof
DE59607535D1 (de) Kosmetische und/oder pharmazeutische zubereitungen
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
DE69704060T2 (de) Tetrahydroisochinolinderivate und ihre pharmazeutische anwendung
DE69524592T2 (de) 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
DE69519368D1 (de) Neue antiandrogenen mitteln pharmazeutische präparate und verwendungen davon
DE4294862T1 (de) Pharmazeutische Komposition
DE59505714D1 (de) Kosmetische und/oder pharmazeutische zubereitungen
DE69415570T2 (de) Esculetin Derivate und pharmazeutische Zusammenstellung
DE69722433D1 (de) Pharmazeutische zubereitungen, welche zidovudin und lamivudine enthalten

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMACEUTICALS INC., BRIDGEWATER, N.J., U

8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT